NanoViricides, Inc. is a development stage company with a unique nanomedicine technology. The Company is developing nanotechnology-based biomimetic anti-viral medicines, that we call "nanoviricides®". Virus-specific nanoviricide drug candidates against five commercially important viral diseases, viz. seasonal and potentially-epidemic influenzas and bird flu, HIV/AIDS, cold sores and genital herpes infection, viral eye diseases, as well as dengue viruses, have demonstrated very high levels of effectiveness.
Unique Find-Encapsulate-Destroy Antiviral Strategy
A "nanoviricide" is an antiviral agent designed by the Company to fool a virus into attaching to this agent in the same way that the virus normally attaches to receptors on a cell surface. Once attached, the flexible nanoviricide glob would wrap around the virus and trap it. In the process, the virus could lose its coat proteins that it needs to bind to a cell. The virus is thus neutralized and effectively destroyed. Nanoviricides are designed to complete the task of dismantling the virus particle without immune system assistance.
Thus nanoviricides represent the next great advance in "Immunotherapeutics" (antibodies and vaccines,) the well established antiviral strategies. Viruses have developed smart strategies to derail immune system function. This results in failure of antibodies and vaccines.
The nanoviricide technology attempts to circumvent virus escape that results from natural changes in virus structure. Despite all such changes, the cell receptor to which a virus binds remains the same. Nanoviricides mimic this conserved feature of virus binding to its host cell receptor. If a virus "escapes" a properly designed nanoviricide, it would have a reduced ability to attach to the cell receptor and would have become much less pathogenic in the process.
Strong Nanomedicine Intellectual Property Portfolio
NanoViricides, Inc. product candidates are based on TheraCour® technology invented and developed by company president and founder Anil R. Diwan, PhD. NanoViricides, Inc. holds an exclusive, worldwide license to this technology for its antiviral drugs. The technology is protected by two very broad international patent applications that cover compositions of matter, processes of manufacture, methods of use, and fields of use. Additional patent applications are expected, and the Company intends to patent each drug separately as well.
Independent Researchers Perform Biological Testing
The Company has several collaborations at leading academic , private and federal laboratories. These independent researchers perform nanoviricides testing against various viral targets. The core intellectual property studies are performed by us. This drug development strategy saves on capital needs and provides unbiased data on our drug candidates.
Advancing Rapidly Towards FDA Submissions
We have filed a pre-IND application for FluCide (NV-INF-1), a novel, first-in-class drug with the FDA. We anticipate moving rapidly after the product development path is defined.
We are developing a state-of-the-art cGMP manufacturing facility to enable production of human clinical batches of nanoviricide drug substances. A world-class team has been put together to work on the facility design, construction, and validation.
We continue to advance our other drugs candidates towards the goal of filing a pre-IND application for each of them in order to define the product development path.
We plan to perform regulatory submissions and file for drug approvals internationally.